GSK's Blenrep Combo Therapy Cuts Risk Of Disease Progression Or Death By Around 50% In Pretreated Multiple Myeloma
Portfolio Pulse from Vandana Singh
GSK's Blenrep combination therapy significantly reduces the risk of disease progression or death in pretreated multiple myeloma patients, according to interim results from the DREAMM-8 phase 3 trial. The therapy showed a statistically significant improvement in progression-free survival compared to the standard of care. However, GSK shares were down 8.74% following the news.
June 03, 2024 | 7:08 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
GSK's Blenrep combination therapy showed significant improvement in progression-free survival in multiple myeloma patients, but GSK shares fell 8.74%.
The positive trial results for Blenrep could lead to future regulatory approvals and increased sales, which is generally positive for GSK's stock. However, the immediate market reaction was negative, possibly due to past regulatory challenges and the recent share price drop.
CONFIDENCE 80
IMPORTANCE 90
RELEVANCE 100